Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR

Christina M. Wyatt; Juhi Chaudhari; Shiyuan Miao; Zipporah Krishnasami; James Hellinger; Andrew S. Levey; Michael Ross; Lene Ryom; Amanda Mocroft; Laurence Brunet; Jennifer Fusco; Lesley A. Inker

doi:10.1016/j.ekir.2020.01.020

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR

Christina M. Wyatt, Juhi Chaudhari, Shiyuan Miao, Zipporah Krishnasami, James Hellinger, Andrew S. Levey, Michael Ross, Lene Ryom, Amanda Mocroft, Laurence Brunet, Jennifer Fusco, Lesley A. Inker

Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	734-737
Number of pages	4
Journal	Kidney International Reports
Volume	5
Issue number	5
DOIs	https://doi.org/10.1016/j.ekir.2020.01.020
State	Published - May 2020

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.ekir.2020.01.020

Cite this

Wyatt, C. M., Chaudhari, J., Miao, S., Krishnasami, Z., Hellinger, J., Levey, A. S., Ross, M., Ryom, L., Mocroft, A., Brunet, L., Fusco, J., & Inker, L. A. (2020). Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR. Kidney International Reports, 5(5), 734-737. https://doi.org/10.1016/j.ekir.2020.01.020

@article{c4efb50233e7401d84d907f21d9c203a,

title = "Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR",

author = "Wyatt, {Christina M.} and Juhi Chaudhari and Shiyuan Miao and Zipporah Krishnasami and James Hellinger and Levey, {Andrew S.} and Michael Ross and Lene Ryom and Amanda Mocroft and Laurence Brunet and Jennifer Fusco and Inker, {Lesley A.}",

note = "Funding Information: The original study was supported by Gilead Sciences, Inc. under an investigator-initiated protocol NCRR L1RR025752 and by the National Institutes of Health / National Center for Advancing Translational Sciences UL1 RR025752 ( Tufts Medical Center ), UL1 RR029887 (Mount Sinai School of Medicine), and UL1 RR025777 ( University of Alabama at Birmingham ). The investigators received additional support for the current analysis from the National Institute of Diabetes and Digestive and Kidney Diseases R01DK112258 and P01DK056492 . Funding Information: The original study was supported by Gilead Sciences, Inc. under an investigator-initiated protocol NCRR L1RR025752 and by the National Institutes of Health/National Center for Advancing Translational Sciences UL1 RR025752 (Tufts Medical Center), UL1 RR029887 (Mount Sinai School of Medicine), and UL1 RR025777 (University of Alabama at Birmingham). The investigators received additional support for the current analysis from the National Institute of Diabetes and Digestive and Kidney Diseases R01DK112258 and P01DK056492.",

year = "2020",

month = may,

doi = "10.1016/j.ekir.2020.01.020",

language = "English (US)",

volume = "5",

pages = "734--737",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR

AU - Wyatt, Christina M.

AU - Chaudhari, Juhi

AU - Miao, Shiyuan

AU - Krishnasami, Zipporah

AU - Hellinger, James

AU - Levey, Andrew S.

AU - Ross, Michael

AU - Ryom, Lene

AU - Mocroft, Amanda

AU - Brunet, Laurence

AU - Fusco, Jennifer

AU - Inker, Lesley A.

N1 - Funding Information: The original study was supported by Gilead Sciences, Inc. under an investigator-initiated protocol NCRR L1RR025752 and by the National Institutes of Health / National Center for Advancing Translational Sciences UL1 RR025752 ( Tufts Medical Center ), UL1 RR029887 (Mount Sinai School of Medicine), and UL1 RR025777 ( University of Alabama at Birmingham ). The investigators received additional support for the current analysis from the National Institute of Diabetes and Digestive and Kidney Diseases R01DK112258 and P01DK056492 . Funding Information: The original study was supported by Gilead Sciences, Inc. under an investigator-initiated protocol NCRR L1RR025752 and by the National Institutes of Health/National Center for Advancing Translational Sciences UL1 RR025752 (Tufts Medical Center), UL1 RR029887 (Mount Sinai School of Medicine), and UL1 RR025777 (University of Alabama at Birmingham). The investigators received additional support for the current analysis from the National Institute of Diabetes and Digestive and Kidney Diseases R01DK112258 and P01DK056492.

PY - 2020/5

Y1 - 2020/5

UR - http://www.scopus.com/inward/record.url?scp=85081208403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081208403&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2020.01.020

DO - 10.1016/j.ekir.2020.01.020

M3 - Article

AN - SCOPUS:85081208403

SN - 2468-0249

VL - 5

SP - 734

EP - 737

JO - Kidney International Reports

JF - Kidney International Reports

IS - 5

ER -

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this